Orphazyme A/S (ORPH) Stock Plummeting After Failure of ORAIALS-01 Trial Announced

Orphazyme A/S (ORPH) stock prices plummeted by 27.77%  after the market opened on May 7th, 2021, bringing the price per share tumbling down to USD$6.12 after the commencing of the trading day. ORAIALS-01 Ends in Failure The company announced on May 7th, 2021 that the ORAIALS-01 pivotal trial of arimoclomol in amyotrophic lateral sclerosis (ALS) […]

Market Globalist
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.